L. Weißbach - Concepedia

Author

L. Weißbach

Charité - Universitätsmedizin Berlin ORCID

Also Known As

H. Rübben, K. Schalkhäuser, L Weissbach, L Weißbach, L. . Weißbach, L. WEISSBACH, L. Weissbach, L. Weißbach, LOTHAR WEISSBACH, LOTHAR WEIßBACH

481

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Barmherzige Brüder Klinikum St. Elisabeth in Straubing Wissenschaftliches Institut der AOK Leipzig University Klinikum Ernst von Bergmann

About

L. Weißbach is an author at Charité - Universitätsmedizin Berlin specializing in urology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	386
2	Geriatrics	1	1	25
3	Health Policy	1	1	25
4	Surgical Oncology	1	1	70
5	Brachytherapy	1	1	70

L. Weißbach

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95 Thomas Wiegel, Dirk Bottke, Ursula Steiner, Journal of Clinical Oncology	2009	815
ORGAN SPARING SURGERY FOR MALIGNANT GERM CELL TUMOR OF THE TESTIS Axel Heidenreich, L. Weißbach, W. Höltl, The Journal of Urology	2001	345
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer Carsten Bokemeyer, J. Beyer, Bernd Metzner, Annals of Oncology Cisplatin-refractory Testicular CancerUrologyGenitourinary CancerMedicineCancer Management	1996	139
Residual Tumor Resection After High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Cancer Oliver Rick, Carsten Bokemeyer, S. Weinknecht, Journal of Clinical Oncology	2004	97
Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression Michael Lein, Manfred P. Wirth, Kurt Miller, European Urology Bone DiseaseZoledronic AcidUrologyBone HealthGenitourinary Cancer	2007	70
Regional Hyperthermia in Conjunction with Definitive Radiotherapy against Recurrent or Locally Advanced Prostate Cancer T3 pN0 M0 Wolfgang Tilly, Johanna Gellermann, R. Graf, Strahlentherapie und Onkologie UrologySurgical OncologyRegional HyperthermiaRadiation TherapyHyperthermia	2005	70
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid Michael Lein, Kurt Miller, Manfred Wirth, The Prostate	2009	44
Morbidity and mortality after surgery for lower urinary tract symptoms: a study of 95 577 cases from a nationwide German health insurance database Christian Gilfrich, Hanna Leicht, Claus Fahlenbrach, Prostate Cancer and Prostatic Diseases UrologyVoiding DysfunctionPelvic Reconstructive SurgeryPatient SafetyOutcomes Research	2016	44
National trends and differences in morbidity among surgical approaches for radical prostatectomy in Germany Jens Uwe Stolzenburg, Iason Kyriazis, Claus Fahlenbrach, World Journal of Urology UrologyRadical ProstatectomyBenign Prostatic HyperplasiaUrogynecologySurgery	2016	25
Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study Friedemann Honecker, Ulrich Wedding, Gerd Kallischnigg, Journal of Cancer Research and Clinical Oncology UrologyHealth PolicyGeriatricsElderly PatientsMedicine	2018	25

Page 1